

Medical Pharmacy Benefit Changes

Neighborhood News – April 2026

Effective **January 1, 2026**, Neighborhood has updated its Medical Pharmacy Benefit for all lines of business to no longer prefer **Prolia/Xgeva (J0897)**. Moving forward, we will **exclusively prefer Osenvelt/Stoboclo (Q5157) or Bilydos/Bilprevda**.

- **No Longer Preferred:**
 - Prolia/Xgeva (J0897)
- **Preferred Products:**
 - Osenvelt/Stoboclo (Q5157)
 - Bilydos/Bilprevda
 - Neither product requires authorization for any indication for all lines of business.
- **Prolia/Xgeva Requirements:**
 - Requires authorization for all indications effective January 1, 2026.
 - Members must have an inadequate response, intolerance, or contraindication to Osenvelt/Stoboclo or Bilydos/Bilprevda before using Prolia/Xgeva.
- **Existing Authorizations:**
 - Members with active authorizations for Prolia/Xgeva can remain on therapy until their authorization ends.
 - Medicare members who have received Prolia/Xgeva within the past 365 days are not subject to Step Therapy requirements.

Effective **January 1, 2026**, Neighborhood has updated its Medical Pharmacy Benefit for the following products for all lines of business.

Pegfilgrastim products:

- Neulasta (pegfilgrastim, J2506), Neulasta OBI (pegfilgrastim OBI, J2506), & Ziextenzo (pegfilgrastim-bmez, Q5120) are the preferred products
- Udenyca (pegfilgrastim-cbqv, Q5111) is no longer preferred

Rituximab products:

- Ruxience (rituximab-pvvr, Q5119), & Riabni (rituximab-arrr, Q5123) are the preferred products

- Truxima (rituximab-abbs, Q5115) is no longer preferred

Trastuzumab products:

- Ontruzant (trastuzumab-dttb, Q5112), & Trazimera (trastuzumab-qyyp, Q5116) are the preferred products
- Kanjinti (trastuzumab-anns, Q5117) is no longer preferred